Q-omics provides the consensus-scored ZNF771 profile across patient tissues and cancer cell-line models. ZNF771 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, ZNF771 is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, ZNF771 RNA expression shows 17,617 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight PAAD, KIRP, and LSCC as cancer lineages where ZNF771 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF771 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF771 survival associations across molecular data types. ZNF771 RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF771 RNA expression–survival associations across cancer types. High ZNF771 expression shows unfavorable associations in LGG, UCS, LIHC and PRAD, but favorable associations in PAAD and LUSC. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for ZNF771 RNA expression.
This table summarizes ZNF771 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRP for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF771. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF771 shows lower tumor expression in KICH and higher tumor expression in KIRP, LIHC, HNSC, LUAD and LUSC. The KIRP box plot shows higher ZNF771 RNA expression in tumor versus normal tissue (log2 FC = +0.915, t-test p < 0.001).
This table shows molecular features associated with ZNF771 in patient tissues and cancer cell lines. In patient samples, ZNF771 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF771 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
